

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2019

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-38022



**MATINAS BIOPHARMA HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**No. 46-3011414**  
(I.R.S. Employer  
Identification No.)

**1545 Route 206 South, Suite 302**  
**Bedminster, New Jersey 07921**  
(Address of principal executive offices) (Zip Code)

**908-443-1860**  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of Each Exchange on Which Registered</u>
Common Stock	MTNB	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input checked="" type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

The aggregate market value of the registrant's voting and non-voting common stock held by non-affiliates of the registrant computed by reference to the price at which the common stock was last sold on September 30, 2019 was approximately \$93.4 million.

As of November 11, 2019, there were 162,740,274 shares of the registrant's common stock, \$0.0001 par value, outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

None.



MATINAS BIOPHARMA HOLDINGS, INC.  
Form 10-Q  
Quarter Ended September 30, 2019

Table of Contents

	<u>Page</u>
<u>PART - I FINANCIAL INFORMATION</u>	
Item 1. <u>FINANCIAL STATEMENTS</u>	1
Item 2. <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	20
Item 3. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	30
Item 4. <u>CONTROLS AND PROCEDURES</u>	30
<u>PART - II OTHER INFORMATION</u>	
Item 1. <u>LEGAL PROCEEDINGS</u>	32
Item 1A. <u>RISK FACTORS</u>	32
Item 2. <u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	32
Item 3. <u>DEFAULTS UNDER SENIOR SECURITIES</u>	32
Item 4. <u>MINE SAFETY DISCLOSURES</u>	32
Item 5. <u>OTHER INFORMATION</u>	32
Item 6. <u>EXHIBITS</u>	32

**Matinas BioPharma Holdings Inc.**  
**Condensed Consolidated Balance Sheets**

	<u>September 30, 2019</u> (Unaudited)	<u>December 31, 2018</u> (Audited)
<b>ASSETS:</b>		
Current assets:		
Cash and cash equivalents	\$ 32,664,782	\$ 12,446,838
Restricted cash	200,000	100,000
Prepaid expenses	1,386,130	538,646
Total current assets	<u>34,250,912</u>	<u>13,085,484</u>
Non-current assets:		
Leasehold improvements and equipment - net	1,806,304	2,042,893
Operating lease right-of-use assets - net	3,877,069	-
Finance lease right-of-use assets - net	141,972	-
In-process research and development	3,017,377	3,017,377
Goodwill	1,336,488	1,336,488
Restricted cash - security deposits	386,000	461,000
Total non-current assets	<u>10,565,210</u>	<u>6,857,758</u>
Total assets	<u>\$ 44,816,122</u>	<u>\$ 19,943,242</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY:</b>		
Current liabilities:		
Accounts payable	\$ 685,802	\$ 295,652
Note payable	-	199,842
Accrued expenses	1,462,767	1,086,868
Stock dividends payable	-	1,174,286
Operating lease liabilities - current	407,026	-
Financing lease liabilities - current	66,743	83,245
Total current liabilities	<u>2,622,338</u>	<u>2,839,893</u>
Non-current liabilities:		
Deferred tax liability	341,265	341,265
Operating lease liabilities - net of current portion	3,809,442	-
Financing lease liabilities - net of current portion	62,331	107,656
Deferred rent liability	-	512,704
Total non-current liabilities	<u>4,213,038</u>	<u>961,625</u>
Total liabilities	<u>6,835,376</u>	<u>3,801,518</u>
Stockholders' equity:		
Series A Convertible preferred stock, stated value \$5.00 per share, 1,600,000 shares authorized as of September 30, 2019 and December 31, 2018; 0 and 1,467,858 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively (liquidation preference - \$0 at September 30, 2019)	-	5,583,686
Series B Convertible preferred stock, stated value \$1,000 per share, 8,000 shares authorized as of September 30, 2019 and December 31, 2018; 4,620 and 4,819 shares issued and outstanding as of September 30, 2019 and December 31, 2018; (liquidation preference - \$4,620,000 at September 30, 2019)	4,023,251	4,196,547
Common stock par value \$0.0001 per share, 250,000,000 shares authorized at September 30, 2019 and December 31, 2018; 162,720,274 and 113,287,670 issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	16,271	11,329
Additional paid-in capital	112,745,948	72,294,921
Accumulated deficit	(78,804,724)	(65,944,759)
Total stockholders' equity	<u>37,980,746</u>	<u>16,141,724</u>
Total liabilities and stockholders' equity	<u>\$ 44,816,122</u>	<u>\$ 19,943,242</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

**Matinas BioPharma Holdings, Inc.**  
**Condensed Consolidated Statements of Operations**  
**Unaudited**

	<u>Three Months Ended September 30,</u>		<u>Nine Months Ended September 30,</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Revenue:				
Contract research revenue	\$ -	-	\$ 89,812	119,750
Costs and expenses:				
Research and development	2,671,365	1,379,525	7,814,842	5,095,110
General and administrative	1,889,892	1,574,712	5,460,023	5,504,559
Total costs and expenses	<u>4,561,257</u>	<u>2,954,237</u>	<u>13,274,865</u>	<u>10,599,669</u>
Loss from operations	(4,561,257)	(2,954,237)	(13,185,053)	(10,479,919)
Sale of New Jersey net operating loss	-	-	1,007,082	-
Other income, net	156,872	18,660	378,151	23,304
Net loss	<u>\$ (4,404,385)</u>	<u>(2,935,577)</u>	<u>\$ (11,799,820)</u>	<u>(10,456,615)</u>
Preferred stock series A accumulated dividends	(45,041)	(146,786)	(338,613)	(440,857)
Preferred stock series B accumulated dividends	<u>(115,500)</u>	<u>(175,075)</u>	<u>(349,500)</u>	<u>(196,924)</u>
Net loss attributable to common shareholders	<u>\$ (4,564,926)</u>	<u>(3,257,438)</u>	<u>\$ (12,487,933)</u>	<u>(11,094,396)</u>
Net loss available for common shareholders per share - basic and diluted	<u>\$ (0.03)</u>	<u>(0.03)</u>	<u>\$ (0.09)</u>	<u>(0.12)</u>
Weighted average common shares outstanding - basic and diluted	<u>156,889,602</u>	<u>94,697,049</u>	<u>139,265,178</u>	<u>94,098,372</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

**Matinas BioPharma Holdings, Inc.**  
**Condensed Consolidated Statement of Stockholders' Equity**  
**Unaudited**

	<u>Redeemable Convertible Preferred Stock A</u>		<u>Redeemable Convertible Preferred Stock B</u>		<u>Common Stock</u>		<u>Additional Paid - in</u>	<u>Accumulated</u>	<u>Total Stockholders'</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Capital</u>	<u>Deficit</u>	<u>Equity</u>
Balance, December 31, 2018	1,467,858	\$ 5,583,686	4,819	\$ 4,196,547	113,287,670	\$ 11,329	\$ 72,294,921	\$ (65,944,759)	\$ 16,141,724
Stock-based compensation	-	-	-	-	-	-	2,059,373	-	2,059,373
Issuance of common stock as compensation for services	-	-	-	-	415,178	41	301,838	-	301,879
Issuance of common stock in exchange for preferred shares A	(1,467,858)	(5,583,686)	-	-	14,678,580	1,468	5,582,218	-	-
Issuance of common stock in exchange for preferred shares B	-	-	(199)	(173,296)	398,000	40	173,256	-	-
Issuance of common stock in public offering, net of stock issuance costs (\$2,315,878)	-	-	-	-	29,471,986	2,947	30,100,359	-	30,103,306
Stock dividends	-	-	-	-	4,468,860	446	2,233,983	(1,060,145)	1,174,284
Net loss	-	-	-	-	-	-	-	(11,799,820)	(11,799,820)
Balance, September 30, 2019	<u>-</u>	<u>\$ -</u>	<u>4,620</u>	<u>\$ 4,023,251</u>	<u>162,720,274</u>	<u>\$ 16,271</u>	<u>\$ 112,745,948</u>	<u>\$ (78,804,724)</u>	<u>\$ 37,980,746</u>

	<u>Redeemable Convertible Preferred Stock A</u>		<u>Redeemable Convertible Preferred Stock B</u>		<u>Common Stock</u>		<u>Additional Paid - in</u>	<u>Accumulated</u>	<u>Total Stockholders'</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Capital</u>	<u>Deficit</u>	<u>Equity</u>
Balance, June 30, 2019	1,467,858	\$ 5,583,686	4,630	\$ 4,031,959	144,205,850	\$ 14,420	\$ 104,601,220	\$ (73,813,195)	\$ 40,418,090
Stock-based compensation	-	-	-	-	-	-	608,129	-	608,129
Issuance of common stock as compensation for services	-	-	-	-	292,984	29	184,597	-	184,626
Issuance of common stock in exchange for preferred shares A	(1,467,858)	(5,583,686)	-	-	14,678,580	1,468	5,582,218	-	-
Issuance of common stock in exchange for preferred shares B	-	-	(10)	(8,708)	20,000	2	8,706	-	-
Stock dividends	-	-	-	-	3,522,860	352	1,761,078	(587,144)	1,174,286
Net loss	-	-	-	-	-	-	-	(4,404,385)	(4,404,385)
Balance, September 30, 2019	<u>-</u>	<u>\$ -</u>	<u>4,620</u>	<u>\$ 4,023,251</u>	<u>162,720,274</u>	<u>\$ 16,271</u>	<u>\$ 112,745,948</u>	<u>\$ (78,804,724)</u>	<u>\$ 37,980,746</u>

	<u>Redeemable Convertible Preferred Stock A</u>		<u>Redeemable Convertible Preferred Stock B</u>		<u>Common Stock</u>		<u>Additional Paid - in</u>	<u>Accumulated</u>	<u>Total Stockholders'</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Capital</u>	<u>Deficit</u>	<u>Equity</u>
Balance, December 31, 2017	1,502,858	\$ 5,716,825	-	\$ -	93,371,129	\$ 9,335	\$ 56,230,347	\$ (51,274,542)	\$ 10,681,965
Stock-based compensation	-	-	-	-	-	-	2,317,801	-	2,317,801
Issuance of common stock as compensation for services	-	-	-	-	713,266	73	534,743	-	534,816
Issuance of common stock in exchange for preferred shares A	(35,000)	(133,139)	-	-	350,000	35	133,104	-	-
Issuance of common stock in exchange for preferred shares B	-	-	(997)	(868,221)	1,994,000	199	868,022	-	-
Stock dividends	-	-	-	-	28,000	3	13,997	(587,143)	(573,143)
Issuance of Preferred Series B net of issuance costs (\$943,750)	-	-	8,000	6,966,668	-	-	-	-	6,966,668
ATM stock sales (net)	-	-	-	-	1,240,848	124	739,032	-	739,156
Issuance of warrants to placement agent	-	-	-	-	-	-	89,582	-	89,582
Net loss	-	-	-	-	-	-	-	(10,456,615)	(10,456,615)
Balance, September 30, 2018	<u>1,467,858</u>	<u>\$ 5,583,686</u>	<u>7,003</u>	<u>\$ 6,098,447</u>	<u>97,697,243</u>	<u>\$ 9,769</u>	<u>\$ 60,926,628</u>	<u>\$ (62,318,300)</u>	<u>\$ 10,300,230</u>

	<u>Redeemable Convertible Preferred Stock A</u>		<u>Redeemable Convertible Preferred Stock B</u>		<u>Common Stock</u>		<u>Additional Paid - in</u>	<u>Accumulated</u>	<u>Total Stockholders'</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Capital</u>	<u>Deficit</u>	<u>Equity</u>
Balance, June 30, 2018	1,467,858	\$ 5,583,686	7,975	\$ 6,944,897	94,236,918	\$ 9,423	\$ 58,784,330	\$ (58,795,579)	\$ 12,526,757
Stock-based compensation	-	-	-	-	-	-	361,599	-	361,599
Issuance of common stock as compensation for services	-	-	-	-	275,477	28	195,411	-	195,439
Issuance of common stock in exchange for preferred shares B	-	-	(972)	(846,450)	1,944,000	194	846,256	-	-
Stock dividends	-	-	-	-	-	-	-	(587,143)	(587,143)
ATM stock sales (net)	-	-	-	-	1,240,848	124	739,032	-	739,156
Net loss	-	-	-	-	-	-	-	(2,935,578)	(2,935,578)
Balance, September 30, 2018	<u>1,467,858</u>	<u>\$ 5,583,686</u>	<u>7,003</u>	<u>\$ 6,098,447</u>	<u>97,697,243</u>	<u>\$ 9,769</u>	<u>\$ 60,926,628</u>	<u>\$ (62,318,300)</u>	<u>\$ 10,300,230</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

**Matinas BioPharma Holdings Inc.**  
**Condensed Consolidated Statements of Cash Flow**  
**Unaudited**

	<b>Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (11,799,820)	\$ (10,456,615)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation and amortization	148,918	156,565
Loss on disposal of equipment	6,417	-
Amortization of operating lease right-of-use assets	336,192	-
Amortization of finance lease right-of-use assets	97,794	-
Change in deferred rent	-	46,262
Stock based compensation expense	2,297,483	2,803,018
<b>Changes in operating assets and liabilities:</b>		
Operating lease liabilities	(262,405)	-
Prepaid expenses	(783,715)	258,914
Accounts payable	390,148	(279,416)
Accrued expenses and other liabilities	375,899	(230,744)
Net cash used in operating activities	<u>(9,193,089)</u>	<u>(7,702,016)</u>
<b>Cash flows from investing activities:</b>		
Purchases of leasehold improvements and equipment	(405,604)	(535,916)
Net cash used in investing activities	<u>(405,604)</u>	<u>(535,916)</u>
<b>Cash flows from financing activities:</b>		
Net proceeds from issuance of Series B convertible preferred stock	-	7,056,250
Net proceeds from ATM sales	-	739,155
Net proceeds from public offering of common stock	30,103,306	-
Payments of capital lease liability - principal	(61,827)	(36,769)
Payments of note payable	(199,842)	(250,173)
Net cash provided by financing activities	<u>29,841,637</u>	<u>7,508,463</u>
Net increase/(decrease) in cash, cash equivalents and restricted cash	20,242,944	(729,469)
Cash, cash equivalents and restricted cash at beginning of period	<u>13,007,838</u>	<u>7,997,937</u>
Cash, cash equivalents and restricted cash at end of period	<u>\$ 33,250,782</u>	<u>\$ 7,268,468</u>
<b>Supplemental non-cash financing and investing activities:</b>		
Right-of-use assets obtained in exchange for liabilities	\$ 4,453,028	\$ -
Preferred stock conversion into common stock - series A	\$ 5,583,686	\$ 133,139
Preferred stock conversion into common stock - series B	\$ 173,296	\$ 868,221
Stock dividends issued	\$ 2,234,429	\$ 14,000
Note payable for insurance premiums	\$ -	\$ 399,683
Stock dividends accrual	\$ 1,060,145	\$ 587,143
Warrants issued to placement agent	\$ -	\$ 89,581
Equipment acquired under capital lease	\$ -	\$ 147,940
Unearned restricted stock grants	\$ 125,600	\$ 126,100

The accompanying notes are an integral part of these condensed consolidated financial statements

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

**Note 1 - Description of Business**

Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

**Note 2 - Liquidity and Plan of Operations**

The Company has experienced net losses and negative cash flows from operations each period since its inception. Through September 30, 2019, the Company had an accumulated deficit of approximately \$78.8 million. The Company’s net loss for the nine months ended September 30, 2019 was approximately \$11.8 million.

The Company has been engaged in developing MAT-9001, its lead product candidate, as well as its lipid nano-crystal (“LNC”) platform delivery technology and a pipeline of associated product candidates since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.

Assuming the Company obtains FDA approval for one or more of its product candidates, which the Company does not expect to receive until 2023 at the earliest, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

To continue to fund operations, on March 19, 2019, the Company completed an underwritten public offering of common stock, generating gross cash proceeds of approximately \$30 million and net proceeds of approximately \$27.8 million. On March 28, 2019, additional shares were sold pursuant to an over-allotment option granted to the underwriters of the public offering, resulting in additional net proceeds to the Company of approximately \$2.3 million (see Note 9).

As of September 30, 2019, the Company had cash and cash equivalents of approximately \$32.7 million and restricted cash of approximately \$0.6 million. The Company believes the cash and cash equivalents on hand are sufficient to fund planned operations through 2020.

**Note 3 - Summary of Significant Accounting Policies**

**Basis of presentation and principles of consolidation**

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

**Use of estimates**

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.



**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

Significant items subject to such estimates and assumptions include, but are not limited to, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, the determination of stock-based compensation, contingent consideration and assets and liabilities acquired in a business combination.

**Cash and cash equivalents**

The Company considers all highly liquid financial instruments with original maturities of three months or less to be cash and cash equivalents. Cash and cash equivalents include cash on hand, bank demand deposits and overnight sweep accounts used in the Company's cash management program.

*Restricted Cash*

The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of September 30, 2019, December 31, 2018, September 30, 2018 and December 31, 2017:

	September 30, 2019	December 31, 2018	September 30, 2018	December 31, 2017
Cash and cash equivalents	\$ 32,665	\$ 12,447	\$ 6,632	\$ 7,307
Restricted cash included in current/long term assets	586	561	636	691
Cash, cash equivalents and restricted cash in the statement of cash flows	<u>\$ 33,251</u>	<u>\$ 13,008</u>	<u>\$ 7,268</u>	<u>\$ 7,998</u>

**Concentration of credit risk**

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation ("FDIC") up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.

**Leasehold improvements and equipment**

Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.

**Goodwill and other intangible assets**

Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that we have the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If we determine this is the case, we perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

A reporting unit is an operating segment, or one level below an operating segment. Historically, we conducted our business in a single operating segment and reporting unit. During the nine months ended September 30, 2019, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company's assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were no impairments of goodwill during the nine months ended September 30, 2019 and 2018.

Indefinite lived intangible assets are composed of in-process research and development ("IPR&D") and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset's carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the nine months ended September 30, 2019 and 2018.

#### Leases

In February 2016, the Financial Accounting Standards Board (the "FASB") established ASC Topic 842, "Leases", by issuing Accounting Standards Update ("ASU") No. 2016-02, which requires lessees to now recognize operating leases on the balance sheet and disclose key information about leasing arrangements. ASC Topic 842 was subsequently amended by ASU No. 2018-01, *Land Easement Practical Expedient for Transition to Topic 842*; ASU No. 2018-10, *Codification Improvements to Topic 842, Leases*; and ASU No. 2018-11, *Targeted Improvements*. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.

The Company adopted the new standard on January 1, 2019 using the modified retrospective transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and accounting policies elections related to this standard:

- Short-term lease accounting policy election allowing lessees to not recognize ROU assets and liabilities for leases with a term of 12 months or less;
- The option to not separate lease and non-lease components in the Company's lease contracts; and
- The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing the capitalization of initial direct costs for any existing leases.

Adoption of this standard resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of approximately \$4.2 million and approximately \$4.5 million, respectively, on the consolidated balance sheet as of January 1, 2019. In addition, the Company reclassified \$0.2 million from leasehold improvements & equipment to finance lease right-of-use assets in connection with the adoption of ASC Topic 842. The Company's accounting for finance leases remained substantially unchanged. Disclosures related to the amount, timing and uncertainty of cash flows arising from leases are included in Note 6, Leases.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

**Preferred stock dividends**

Prior to its automatic conversion on July 29, 2019, shares of Series A Preferred Stock earned dividends at a rate of 8.0% once per year on the first, second and third anniversary of July 29, 2016, which was paid to the holders of such Series A Preferred Stock in the form of shares of the Company's common stock when converted. In addition, and subject to provisions detailed more fully in Footnote 9, shares of Series B Preferred Stock earn dividends at rates of 10%, 15% and 20% once per year on the first, second and third anniversary, respectively, of June 19, 2018. Dividends are payable to holders of the Series B Preferred Stock in the form of shares of the Company's common stock. Preferred stock dividends do not require declaration by the Board of Directors and are accrued annually as of the date the dividend is earned in an amount equal to the applicable rate of the stated value.

**Business combination**

The Company accounts for business combinations using the acquisition method of accounting which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the acquisition date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Transaction costs are expensed as incurred and reported in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company's operating results from the date of acquisition.

**Beneficial conversion feature of convertible preferred stock**

The Company accounts for the beneficial conversion feature on its convertible preferred stock in accordance with Accounting Standards Codification ("ASC") 470-20 *Debt with Conversion and Other Options*. The Beneficial Conversion Feature ("BCF") of convertible preferred stock is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of convertible preferred stock when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved.

To determine the effective conversion price, the Company first allocates the proceeds received to the convertible preferred stock and then uses those allocated proceeds to determine the effective conversion price. If the convertible instrument is issued in a basket transaction (i.e., issued along with other freestanding financial instruments), the proceeds should first be allocated to the various instruments in the basket. Any amounts paid to the investor when the transaction is consummated (e.g., origination fees, due diligence costs) represent a reduction in the proceeds received by the issuer. The intrinsic value of the conversion option is measured using the effective conversion price for the convertible preferred stock on the proceeds allocated to that instrument. The effective conversion price represents proceeds allocable to the convertible preferred stock divided by the number of shares into which it is convertible. The effective conversion price is then compared to the per share fair value of the underlying shares on the commitment date.

The BCF is recognized by allocating the intrinsic value of the conversion option to additional paid-in capital, resulting in a discount on the convertible preferred stock. This discount is accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. The intrinsic value of the BCF is recognized as a deemed dividend on convertible preferred stock over the period specified in the guidance.

**Sale of net operating losses (NOLs)**

The Company recognized approximately \$1.0 million and \$0 for the nine months ended September 30, 2019 and 2018, respectively, in connection with the sale of state net operating losses and state research and development credits to a third party under the New Jersey Technology Business Tax Certificate Program. The Company did not recognize any income from the sale of NOLs during the three months ended September 30, 2019 and 2018.

**Income taxes**

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. The Company classifies interest and penalties related to uncertain income tax positions in income tax expense in the consolidated statement of operations. The Company did not recognize any income tax related interest or penalties during the nine months ended September 30, 2019 and 2018, nor has the company recognized any liabilities for uncertain tax positions in its consolidated financial statements.

The Company is subject to examination by the Internal Revenue Service of its federal income tax returns and by state tax authorities for state jurisdictions. Since the Company incurred net operating losses in every tax year since inception, all income tax returns are subject to examination and adjustments for at least three years following the year in which the tax attributes generated in those years are utilized.

**Fair value measurements**

The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity's pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

- Level 1 - Quoted prices for identical assets or liabilities in active markets.
- Level 2 - Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.
- Level 3 - Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

The carrying amounts of cash and cash equivalents, current portion of restricted cash, accounts receivable, prepaid expenses, accounts payable, note payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments.

**Basic and diluted net loss per common share**

Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares outstanding during the period. Diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options and warrants and conversion of preferred stock, would have an anti-dilutive effect.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

The following table provides the number of shares of common stock issuable upon the exercise of stock options, warrants and conversion of preferred stock, which have been excluded from the diluted loss per share calculation as the inclusion would be anti-dilutive for the three and nine months ended September 30, 2019 and 2018:

	As of September 30,	
	2019	2018
Stock options	16,859	11,455
Convertible preferred stock and accrued dividends upon conversion	9,240	28,685
Warrants	5,799	5,802
Total	<u>31,898</u>	<u>45,942</u>

**Revenue recognition**

The Company's revenues consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation ("CFF"). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. As this contract is currently the Company's only contract with a customer, disaggregation of revenue is not required.

**Research and development, legal fees and other direct costs**

Research and development costs are charged to expenses as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

**Recent accounting standards**

In January 2017, the FASB issued ASU No. 2017-04 "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment". The amendment simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. Instead an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We are required to apply the amendments for the annual or any interim goodwill impairment tests in fiscal years beginning on January 1, 2020. We have evaluated this standard and believe it will not have a material impact on our consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, "Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The Company adopted the guidance on January 1, 2019. The adoption did not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, "Changes to Disclosure Requirements for Fair Value Measurements", which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

On January 1, 2019, the Company adopted the final rule under SEC Release No. 33-10532, *Disclosure Update and Simplification*, which amended certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The Company has updated its consolidated financial statements to include a reconciliation of the beginning balance to the ending balance of stockholders' equity for each period for which a statement of comprehensive income is filed.

**Note 4 – Leasehold Improvements and Equipment**

Leasehold improvements and equipment consist of the following as of September 30, 2019 and December 31, 2018:

	<b>September 30, 2019</b>	<b>December 31, 2018</b>
Lab equipment	\$ 1,437	\$ 1,054
Equipment under capital lease	-	272
Leasehold improvements	878	1,156
Total	2,315	2,482
Less: accumulated depreciation and amortization	509	439
Leasehold improvements and equipment, net	<u>\$ 1,806</u>	<u>\$ 2,043</u>

Depreciation and amortization expense was approximately \$149 thousand and \$156 thousand for the nine months ended September 30, 2019 and 2018, respectively.

**Note 5 – Accrued Expenses**

Accrued Expenses consist of the following as of September 30, 2019 and December 31, 2018:

	<b>September 30, 2019</b>	<b>December 31, 2018</b>
Payroll and incentives	\$ 222	\$ 632
General and administrative expenses	440	190
Research and development expenses	801	233
Other	-	32
Total	<u>\$ 1,463</u>	<u>\$ 1,087</u>

**Note 6 – Leases**

The Company has various lease agreements with terms up to 10 years, including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company's incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

The Company's operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company's finance leases.

The Company incurred lease expense for its operating leases of approximately \$203 thousand and \$610 thousand for the three and nine months ended September 30, 2019, respectively, and \$186 thousand and \$559 thousand for the three and nine months ended September 30, 2018, respectively.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

The Company incurred interest expense on its finance leases of approximately \$3 thousand and \$9 thousand for the three and nine months ended September 30, 2019, respectively, and \$3 thousand and \$9 thousand for the three and nine months ended September 30, 2018, respectively. The Company incurred amortization expense on its finance lease right-of-use assets of approximately \$25 thousand and \$98 thousand for the three and nine months ended September 30, 2019, respectively, and \$28 thousand and \$71 thousand for the three and nine months ended September 30, 2018, respectively.

The following table presents information about the amount and timing of liabilities arising from the Company's operating and finance leases as of September 30, 2019:

<b>Maturity of Lease Liabilities</b>	<b>Operating Lease Liabilities</b>	<b>Finance Lease Liabilities</b>
2019	\$ 185	\$ 22
2020	753	60
2021	684	34
2022	645	19
2023	677	2
Thereafter	\$ 2,914	\$ -
Total undiscounted operating lease payments	\$ 5,858	137
Less: Imputed interest	1,642	\$ 8
Present value of operating lease liabilities	<u>\$ 4,216</u>	<u>\$ 129</u>
Weighted average remaining lease term	7.7	2.3
Weighted average discount rate	8.4%	7.8%

**Note 7 – Commitments**

*Research and development agreements*

The Company has financial obligations resulting from Cooperative Research and Development Agreements ("CRADAs") entered into with the with the National Institute of Allergy and Infectious Diseases ("NIH") as follows:

- On February 19, 2016, the Company agreed to provide funds in the amount of \$200,000 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of encochleated drug products in patients with fungal, bacterial, or viral infections. The initial term of the CRADA was three years. On April 16, 2019, the Company renewed the CRADA for an additional three years with an annual funding commitment of \$200,000.
- On April 2, 2019, the Company agreed to provide funds in the amount of \$157,405 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of encochleated drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.

In addition, in the course of normal business operations, the Company enters into agreements with contract service providers to assist in the performance of research & development and manufacturing activities. Expenditures to these third parties represent significant costs in clinical development and may require upfront payments and long-term commitments of cash. Subject to required notice periods and obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

*Royalty payment rights*

On September 12, 2016 the Company conducted a final closing of a private placement offering to accredited investors of shares of the Company's Series A Preferred Stock. As part of this offer, the investors received royalty payment rights if and when the Company generates sales of its MAT2203 or MAT2501 product candidates. Pursuant to the terms of the Series A Certificate of Designation, the Company may be required to pay royalties of up to \$35 million per year. If and when the Company obtains FDA or EMA approval of MAT2203 and/or MAT2501, which the Company does not expect to occur before 2020, if ever, and/or if the Company generates sales of such products, or the Company receives any proceeds from the licensing or other disposition of MAT2203 or MAT2501, the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the "Royalty Payment Rights") equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of \$25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of \$10 million per calendar year. The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033.

*License agreement*

Through the acquisition of Aquarius, the Company acquired a license from Rutgers University, The State University of New Jersey (successor in interest to the University of Medicine and Dentistry of New Jersey) for the LNC platform delivery technology. The Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of \$100,000 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of initially \$10,000, increasing to \$50,000 over the term of the license agreement.

**Note 8 – Related Parties**

*Aegis Capital Corp. and Mr. Adam Stern*

Mr. Adam Stern, a director of the Company, has been Head of Private Equity Banking at Aegis Capital Corp. ("Aegis") and CEO of SternAegis Ventures since 2012. Aegis acted as a selected dealer for our public offering of Series B Preferred Stock in June 2018, which raised gross proceeds of \$8 million. In connection with the offering the Company agreed to issue placement agent warrants to purchase that number of shares of common stock equal to 1.5% of the aggregate number of shares of common stock underlying the shares of Series B Preferred Stock sold in the offering (not including any shares payable pursuant to the contemplated dividend thereunder). A total of 240,000 warrants were issued, of which Adam Stern and Aegis were collectively issued 81,080.

No related party transactions were entered into during the three and nine months ended September 30, 2019. Except as disclosed above regarding Aegis and Mr. Adam Stern, no other related party transactions were entered into during the three and nine months ended September 30, 2018.

**Note 9 – Stockholders' Equity**

**Common Stock**

On March 19, 2019, the Company closed an underwritten public offering of its common stock. This offering was made pursuant to an underwriting agreement between the Company and BTIG, LLC. The offering resulted in the sale of 27,272,727 shares to the public at a price of \$1.10 per share. The Company generated gross proceeds of \$30.0 million. Net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses are approximately \$27.8 million. In addition, the Company granted the underwriters a 30-day option (the "option") to purchase up to an additional 4,090,909 shares of common stock subject to the same terms and conditions. On March 28, 2019, an additional 2,199,259 shares were sold pursuant to the option at a price of \$1.10 per share, resulting in net proceeds to the Company of approximately \$2.3 million.



**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

**Preferred Stock**

In accordance with the Certificate of Incorporation, the Company is authorized to issue 10,000,000 preferred shares at a par value of \$0.001. In connection with a private placement of Series A Preferred Stock, on July 26, 2016, the Company filed the Series A Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series A Preferred Stock. Pursuant to the Series A Certificate of Designation, the Company designated 1,600,000 shares of the Company's previously undesignated preferred shares as Series A Preferred Stock. In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated 8,000 shares of the Company's previously undesignated preferred shares as Series B Preferred Stock.

Series A Preferred Stock

On July 29, 2019, the Company effected a mandatory conversion of all then outstanding shares of Series A Preferred Stock in accordance with terms of the underlying Certificate of Designation. The conversion resulted in the issuance of 14,678,580 shares of the Company's common stock. In addition, the Company issued 3,522,860 shares of common stock as payment-in-kind for dividends that were accrued to shareholders of Series A Preferred Stock.

Conversion:

Prior to the automatic conversion of the Series A Preferred Stock on July 29, 2019, each share of Series A Preferred Stock was convertible at the option of the holder into such number of shares of the Company's common stock equal to the number of shares of Series A Preferred Stock to be converted, multiplied by the stated value of \$5.00 per share (the "Stated Value"), divided by the Conversion Price in effect at the time of the conversion (the initial conversion price is \$0.50, subject to adjustment in the event of stock splits, stock dividends, and a "fundamental transaction" as defined below). Based on the conversion price and number of shares outstanding, the Series A Preferred Stock were converted into 14,678,580 shares of common stock. A "fundamental transaction" means: (i) a merger or consolidation of the Company with or into another entity, (ii) any sale of all or substantially all of our assets in one transaction or a series of related transactions, or (iii) any reclassification of our Common Stock or any compulsory share exchange by which Common Stock is effectively converted into or exchanged for other securities, cash or property. Each share of Series A Preferred Stock will automatically convert into common stock upon the earlier of (i) notice by the Company to the holders that the Company has elected to convert all outstanding Series A Preferred Stock; provided however that in the event the Company elects to force automatic conversion pursuant to this clause (i), the conversion date for purposes of calculating the accrued dividend (as defined below) is deemed to be July 29, 2019, (ii) July 29, 2019, (iii) the approval of the Company's MAT2203 product candidate by the FDA or the EMA (the "Regulatory Approval") or (iv) the Regulatory Approval of the Company's MAT2501 product candidate.

Beneficial Conversion Feature – Series A Preferred Stock (deemed dividend):

Prior to the automatic conversion of the Series A Preferred Stock on July 29, 2019, each share of Series A Preferred Stock was convertible into shares of common stock, at any time at the option of the holder at a conversion price of \$0.50 per share.

Based on the guidance in ASC 470-20-20, the Company determined that a beneficial conversion feature existed, as the effective conversion price for the Series A Preferred Stock at issuance was less than the fair value of the common stock which the preferred shares are convertible into. A beneficial conversion feature based on the intrinsic value of the date of issuances for the Series A Preferred Stock was approximately \$4.4 million.

Liquidity Value and Dividends:

Pursuant to the Certificate of Designation, the Series A Preferred Stock accrued dividends at a rate of 8.0% once per year on the first three anniversaries of July 29, 2016, which were paid to the holders of such Series A Preferred Stock in shares of common stock upon conversion. Dividends of approximately \$1.8 million, representing 3,522,860 shares of common stock, were accrued as paid-in-kind through July 29, 2019, with \$0.6 million accrued in each of 2019, 2018 and 2017.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

Royalty:

The Series A Preferred Stock includes the right, as a group, to receive: (i) a royalty of 4.5% of the net sales of the Company's MAT2203 and MAT2501 product candidates, in each case from and after the date, respectively, such product candidate has received FDA or EMA approval, and (ii) a royalty of 7.5% of the proceeds, if any, received by the Company in connection with the licensing or other disposition by the Company of MAT2203 and/or MAT2501 ("Royalty Payment Rights"). The royalty is payable so long as the Company has valid patents covering MAT2203 and MAT2501, as applicable. The Royalty Payment Rights are unsecured obligations of the Company. The royalty payment will be allocated to the holders based on their pro rata ownership of vested Series A Preferred Stock. The royalty rights that are part of the Series A Preferred Stock vested in equal thirds, on July 29, 2017, July 29, 2018, and July 29, 2019 (each a "Vesting Date") Following the July 29, 2019 conversion of Series A Preferred Stock, the Royalty Payment Rights may be transferred subject to available exemption from registration under applicable securities laws. These rights were not separable free-standing instruments requiring bifurcation at the date of transaction. The Company may recognize a deemed dividend for the estimated fair value of the vested portion of Royalty Payment Rights in future periods. As of September 30, 2019, no accrual has been recorded for royalty payments as it is not probable at this time that any amount will be paid.

Series B Preferred Stock

On June 19, 2018, the Company entered into a placement agency agreement with ThinkEquity, a Division of Fordham Financial Management, Inc., as placement agent, relating to the offering, issuance and sale of up to 8,000 shares of the Company's Series B Convertible Preferred Stock, par value \$0.0001 per share with a stated value of \$1,000 per share which are convertible into an aggregate of up to 16,000,000 shares of the Company's common stock at an initial conversion price of \$0.50 per share. The offering also included up to an additional 7,200,000 shares of common stock issuable upon payment of dividends under the Series B Preferred Stock. The offering closed on June 21, 2018 raising a gross amount of \$8 million with net proceeds of \$7.1 million after deducting issuance costs. The placement agent received 7% commission on the gross proceeds, 1% of the gross proceeds to cover non-accountable expenses and 240,000 warrants fair valued at approximately \$89,000 treated as a reduction to gross proceeds, that are exercisable over a 5-year period at an exercise price of \$0.75 per share.

As of September 30, 2019, there were 4,620 shares of Series B Preferred Stock outstanding.

Conversion:

*Optional Conversion.* Subject to the Beneficial Ownership Limitation (defined below), each share of Series B Preferred Stock will be convertible into shares of the Company's common stock at any time at the option of the holder at an initial conversion price of \$0.50 per share subject to adjustment for reverse splits, stock combinations and similar changes as provided in the Certificate of Designation. Based on the current conversion price and number of shares outstanding, the Series B Preferred Stock is convertible into 9,240,000 shares of common stock. Dividends will not accrue and will not be paid following optional conversion. During the nine months ended September 30, 2019 and 2018, 199 and 997 shares, respectively, of Series B preferred stock were converted into shares of common stock.

*Automatic Conversion.* Subject to the Beneficial Ownership Limitation described below, each share of Series B Preferred Stock shall automatically convert into 2,000 shares of the Company's common stock at an initial conversion price of \$0.50 per share upon the earlier of (i) the first FDA approval of one of our product candidates, (ii) the 36-month anniversary of the of the filing of the Certificate of Designation for the Series B Preferred Stock with the Secretary of State of Delaware (the "COD Effective Date" which is June 19, 2018) or (iii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series B Preferred Stock. In the event the Series B Preferred Stock automatically converts into common stock prior to the 36 month anniversary of the COD Effective Date, the holder on the date of such conversion shall also be entitled to receive those dividends which would have been payable after the conversion date, as if the shares of Series B Preferred Stock had remained unconverted and outstanding through the 36 month anniversary of the COD Effective Date. Such dividend amount shall be payable as set forth above in shares of common stock upon such automatic conversion.

*Beneficial Conversion Feature.* The Optional and Automatic conversion features do not contain a BCF as the effective conversion price for the Series B Preferred Stock at issuance was equal to the fair value of the common stock into which the preferred shares are convertible into.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

*Beneficial Ownership Limitation.* The Company may not affect any optional or automatic conversion of the Series B Preferred Stock, or issue shares of common stock as dividends and a holder does not have the right to convert any portion of the Series B Preferred Stock to the extent that, after giving effect to such conversion such holder would beneficially own in excess of the Beneficial Ownership Limitation, or such holder, together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates, would beneficially own in excess of the Beneficial Ownership Limitation. The "Beneficial Ownership Limitation" is 4.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon conversion of Series B Preferred Stock held by the applicable holder. A holder may, prior to issuance of the Series B Preferred Stock or, with 61 days prior notice to us, elect to increase or decrease the Beneficial Ownership Limitation; provided, however, that in no event may the Beneficial Ownership Limitation exceed 9.99%.

**Liquidity Value and Dividends:**

*Dividends.* Subject to the Beneficial Ownership Limitation described above, holders of the Series B Preferred Stock are entitled to receive dividends payable in the Company's common stock as follows: (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 12 month anniversary of the COD Effective Date, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 24-month anniversary of the COD Effective Date and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 36-month anniversary of the COD Effective Date. In the event a purchaser in this offering no longer holds Series B Preferred Stock as of the 12-month anniversary, the 24-month anniversary or the 36-month anniversary, such purchaser will not be entitled to receive any dividends on such anniversary date. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2019, the Company paid the 12-month anniversary dividend payment of 10%, totaling 946,000 shares of common stock.

In the event a fundamental transaction is consummated prior to the automatic conversion of the Series B Preferred Stock, the dividends will be accelerated and paid to the extent not previously paid. In addition, holders of Series B Preferred Stock will be entitled to receive dividends equal, on an as-if-converted to shares of common stock basis, and in the same form as dividends actually paid on shares of the common stock when, as, and if such dividends are paid on shares of the common stock. Notwithstanding the foregoing, to the extent that a holder's right to participate in any dividend in shares of common stock to which such holder is entitled would result in such holder exceeding the Beneficial Ownership Limitation, then such holder shall not be entitled to participate in any such dividend to such extent and the portion of such shares that would cause such holder to exceed the Beneficial Ownership Limitation shall be held in abeyance for the benefit of such holder until such time, if ever, as such holder's beneficial ownership thereof would not result in such holder exceeding the Beneficial Ownership Limitation.

Pursuant to its Certificate of Designation, the liquidation value of a share of Series B Preferred Stock is equal to the stated value of \$1,000 per share (as adjusted for stock splits, stock dividends, combinations or other recapitalizations of the Series A Preferred Stock) plus any earned but unpaid dividends.

**Warrants**

The Company has issued two types of warrants: (i) investor warrants and (ii) placement agent warrants. All warrants are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the investor warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company's capital stock or other similar changes to the equity structure of the Company.

For 20 million investor warrants issued in 2015, the Company may call the warrants at any time the common stock trades above \$3.00 for twenty (20) consecutive days following the effectiveness of the registration statement covering the resale of the shares of common stock underlying the warrants, provided that the warrants can only be called if such registration statement is current and remains effective at the time of the call and provided further that the Company can only call the investor warrants for redemption, if it also calls all other warrants for redemption on the terms described above.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

The placement agent warrants do not have a redemption feature. They may be exercised on a cashless basis at the Company's option.

The investor warrants and placement agent warrants are classified as equity instruments.

As of September 30, 2019, the Company had outstanding warrants to purchase an aggregate of 5,799,429 shares of common stock at exercise prices ranging from \$0.50 to \$0.75 per share. A summary of warrants outstanding as of September 30, 2019 is presented below, all of which are fully vested:

	<b>Shares</b>
Outstanding at December 31, 2017	5,958**
Issued	240
Exercised	-
Tendered	-
Expired	(399)
Outstanding at December 31, 2018	5,799*
Issued	-
Exercised	-
Tendered	-
Expired	-
Outstanding at September 30, 2019	5,799*

\* Weighted average exercise price for outstanding warrants is \$0.61.

\*\* Weighted average exercise price for outstanding warrants is \$0.70.

**Note 10 – Stock-based Compensation**

The Company's Amended and Restated 2013 Equity Compensation Plan (the "Plan") provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. Options under the Plan may be granted at prices not less than 100% of the fair value of the shares on the date of grant as determined by the Compensation Committee of the Board of Directors. The Compensation Committee determines the period over which the options become exercisable subject to certain restrictions as defined in the Plan, with the current outstanding options generally vesting over three or four years. The term of the options is no longer than ten years. As of September 30, 2019, the Company had 22,421,644 shares of common stock authorized for issuance under the Plan.

With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January (with Board approval), commencing January 1, 2015 in an amount up to four percent (4%) of the total number of shares of common stock outstanding on the preceding December 31st.

The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Research and Development	\$ 185	\$ 101	\$ 834	\$ 787
General and Administrative	486	404	1,463	2,016
Total	\$ 671	\$ 505	\$ 2,297	\$ 2,803

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

The following table contains information about the Company's stock plan at September 30, 2019:

	<u>Awards Reserved for Issuance</u>	<u>Awards Issued</u>	<u>Awards Available for Grant</u>
2013 Equity Compensation Plan	22,422*	19,132**	3,289

\* Increased by 4,532 thousand on January 1, 2019, representing 4% of the total number of shares of common stock outstanding on December 31, 2018.

\*\* Includes both stock grants and option grants

The following table summarizes the Company' stock option activity and related information for the period from December 31, 2018 to September 30, 2019 (options in thousands):

	<u>Number of Options</u>	<u>Weighted Average Exercise Price</u>	<u>Weighted Average Contractual Term in Years</u>
Outstanding at December 31, 2018	13,457	\$ 1.13	6.2
Granted	3,595	\$ 1.03	
Exercised			
Forfeited	(137)	\$ 1.22	
Cancelled			
Expired	(56)	\$ 2.32	
Outstanding at September 30, 2019	<u>16,859</u>	<u>\$ 1.11</u>	<u>6.3</u>

As of September 30, 2019, the number of vested shares underlying outstanding options was 11,313,021 at a weighted average exercise price of \$1.16. The aggregate intrinsic value of in-the-money options outstanding as of September 30, 2019 was \$0.6 million. As of September 30, 2019, there was approximately \$3.9 million of total unrecognized share-based compensation. Such costs are expected to be recognized over a weighted average period of approximately 2.8 years.

All outstanding options expire ten years from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with 25% of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives.

During the nine months ended September 30, 2019 and 2018, the Company granted restricted stock awards for 415,178 and 713,266 shares of common stock, respectively. These awards are typically granted to members of the Board of Directors as payment in lieu of cash fees or as payment to a vendor pursuant to a consulting agreement. The Company values restricted stock awards at the fair market value on the date of grant. The Company recorded the value of these restricted awards as general and administrative expense of approximately \$238 thousand and \$485 thousand in the condensed consolidated statement of operations for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, there was \$122 thousand of total unrecognized compensation costs related to 200,000 non-vested restricted stock grants which are expected to be recognized over a weighted-average period of 0.5 years.

**MATINAS BIOPHARMA HOLDINGS, INC.**  
**Notes to Unaudited Condensed Consolidated Financial Statements**  
**(Tabular dollars and shares in thousands, except per share data)**

The Company recognizes compensation expense for stock option awards and restricted stock awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of awards granted subject to a vendor's consulting agreement, whereby the award vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Beginning January 1, 2019, stock options issued to consultants are recorded at fair value on the date of grant and the award is recognized as an expense on a straight-line basis over the requisite service period. The following weighted-average assumptions were used to calculate share-based compensation for the comparative periods presented:

	<b>For the Three Months Ended</b>		<b>For the Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Volatility	108.03-108.06%	105.85-109.95%	108.03-111.34%	105.85-109.95%
Risk-free interest rate	1.59-1.89%	2.84-3.00%	1.59-2.65%	2.29-3.00%
Dividend yield	0.0%	0.0%	0.0%	0.0%
Expected life	6.0 years	6.0 years	6.0 years	6.0 years

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the "simplified method" described in Staff Accounting Bulletin (SAB) 107 to estimate the expected term of its stock-based awards.

The expected stock price volatility assumption is based the Company's historical stock price volatility.

**Note 11 - Subsequent Events**

None

## Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2018 and in other reports we file with the Securities and Exchange Commission, particularly those under "Risk Factors." Dollars in tabular format are presented in thousands, except per share data, or otherwise indicated.*

### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential" and other similar words and expressions of the future.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

- our ability to raise additional capital to fund our operations and to develop our product candidates, including MAT9001 and MAT2203;
- our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and product approvals;
- our history of operating losses in each year since inception and the expectation that we will continue to incur operating losses for the foreseeable future;
- our dependence on product candidates, which are still in an early development stage;
- our reliance on the proprietary LNC drug delivery technology platform, which is licensed to us by Rutgers University;
- our ability to manufacture batches of our product candidates in accordance with the standards of Good Manufacturing Practices, which are required for pre-clinical and clinical trials and, subsequently, if regulatory approval is obtained for any of our products, our ability to manufacture commercial quantities;
- our ability to complete required clinical trials for our product candidates and obtain approval from the FDA or other regulatory agents in different jurisdictions;
- our expectations of the attributes of our product and development candidates, including pharmaceutical properties, efficacy, safety and dosing regimens;
- our dependence on third parties, including manufactures and contract research organizations ("CROs") (including, without limitation, the NIH) to conduct our clinical trials;

- our ability to maintain or protect the validity of our patents and other intellectual property;
- our ability to retain and recruit key personnel;
- our ability to internally develop new inventions and intellectual property;
- interpretations of current laws and the passages of future laws;
- our lack of a sales and marketing organization and our ability to commercialize products, if we obtain regulatory approval, whether alone or through potential future collaborators;
- our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates;
- the accuracy of our estimates regarding expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;
- developments and projections relating to our competitors or our industry;
- our ability to adequately support growth; and
- the factors listed under the headings “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, elsewhere in this report and other reports that we file with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith, and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

#### **Overview**

We are a clinical-stage biopharmaceutical company focused on creating value through the development of our lead product candidate, MAT9001, a highly purified, prescription-only omega-3 free fatty acid formulation specifically designed for the treatment of cardiovascular and metabolic conditions and (ii) the application of our lipid nano-crystal (LNC) platform delivery technology to solve complex challenges relating to the delivery of small molecules, gene therapies, vaccines, proteins and peptides, including MAT2203, our lead product candidate based on the LNC technology. Based upon MAT9001’s unique mixture of highly purified omega-3 free fatty acids and our observations of MAT9001’s enhanced bioavailability and potency as compared to Amarin Corporation’s Vascepa® (icosapent ethyl) in our initial head-to-head pharmacokinetic (PK) and pharmacodynamic (PD), or PK/PD, clinical study, we believe that the results of our forthcoming targeted clinical development activities and related clinical investigations may yield an improved therapeutic profile compared to currently-existing therapies.

We are focused on creating value through the strategic development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of our LNC platform delivery technology to solve complex challenges relating to the delivery of small molecules, gene therapies, proteins/peptides, and vaccines. Key elements of our strategy include:

- Strategically advancing MAT9001 into clinical development toward an initial indication for the treatment of severe hypertriglyceridemia ( $\geq 500$  mg/dL) (SHTG) with the goal of creating additional data further demonstrating the differentiation of MAT9001 from other prescription omega-3 drugs being used to treat a mixed dyslipidemic patient population in a rapidly emerging and expanding omega-3 market.



- Expanding application of our lipid nano-crystal (LNC) delivery platform into the gene therapy space through collaborations with sophisticated and well-resourced biotech and pharmaceutical companies in innovative areas of medicine.
- Driving MAT2203 to efficacy data in the treatment of cryptococcal meningitis, an area of significant unmet medical need, with the non-dilutive financial support of the NIH

We have incurred losses for each period from our inception. For the nine months ended September 30, 2019 and 2018, our net loss was approximately \$11.8 million and \$10.5 million, respectively. We expect to incur significant expenses and operating losses over the next several years. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would impact our going concern and would have a negative impact on our financial condition and our ability to pursue our business strategy and continue as a going concern. We will need to generate significant revenues to achieve profitability, and we may never do so.

## Financial Operations Overview

### Revenue

During the nine months ended September 30, 2019 and 2018, we generated contract research revenue of approximately \$90 thousand and \$120 thousand, respectively, resulting from a grant with the Cystic Fibroses Foundation. Our ability to generate product revenue, which we do not expect to occur until 2023 at the earliest, if ever, will depend heavily on the successful development and eventual commercialization of our early-stage product candidates. The Company adopted ASC 606, *Revenue from Contracts with Customers* (“ASC 606”) as of January 1, 2018 which did not result in any changes to the opening balances in our consolidated financial statements or amounts reported in the comparative period consolidated financial statements.

### Research and Development Expenses

Research and development expenses consist of costs incurred for the development of product candidates and advancement of our LNC delivery technology platform, which include:

- the cost of conducting pre-clinical work;
- the cost of acquiring, developing and manufacturing pre-clinical and human clinical trial materials;
- costs for consultants and contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations;
- expenses incurred under agreements with contract research organizations, or CROs, including the NIH, that conduct our pre-clinical or clinical trials; and
- employee-related expenses, including salaries and stock-based compensation expense for those employees involved in the research and development process.

The table below summarizes our direct research and development expenses for our product candidates and development platform for the three and nine months ended September 30, 2019 and 2018. Our direct research and development expenses consist principally of external costs, such as fees paid to contractors, consultants, analytical laboratories and CROs and/or the NIH, in connection with our development work. We typically use our employee and infrastructure resources for manufacturing clinical trial materials, conducting product analysis, study protocol development and overseeing outside vendors. Included in “Internal Staffing, Overhead and Other” below is the cost of laboratory space, supplies, research and development (R&D) employee costs (including stock-based compensation), travel and medical education.

(Dollars in thousands)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
Direct research and development expenses:				
Manufacturing process development	\$ 353	\$ 58	\$ 462	\$ 398
Preclinical trials	487	249	1,063	856
Clinical development	413	6	1,746	441
Regulatory	37	19	170	111
Internal staffing, overhead and other	1,381	1,048	4,374	3,289
Total research and development	<u>\$ 2,671</u>	<u>\$ 1,380</u>	<u>\$ 7,815</u>	<u>\$ 5,095</u>

Research and development activities are central to our business model. We expect our research and development expenses to increase because product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage human trials. In addition, we will look to strategically expand the use of our drug platform technology through additional development work. During 2019, we are focused on advancing our lead product candidate, MAT9001 into clinical development toward an initial indication for the treatment of severe hypertriglyceridemia, expanding application of our LNC delivery platform through collaborations with third parties, and driving MAT2203 to efficacy data in the treatment of cryptococcal meningitis.

#### **General and Administrative Expenses**

General and administrative expenses consist principally of salaries and related costs for personnel in executive and finance functions. Other general and administrative expenses include facility costs, insurance, investor relations expenses, professional fees for legal, patent review, consulting and accounting/audit services.

We anticipate that our general and administrative expenses will increase during 2019 due to the increased expenses related to our status as a publicly traded company, including expenses in support of compliance with the requirements of Section 404 of the Sarbanes Oxley Act as well as investor relations, protection of our intellectual property and insurance costs.

#### **Sale of New Jersey Net Operating Loss**

Income obtained from selling unused net operating losses ("NOLs") and unused research tax credits under the New Jersey Technology Business Tax Certificate Program was approximately \$0 and \$1.0 million for the three and nine months ended September 30, 2019, respectively. We did not recognize any income from the sale of NOLs during the three and nine months ended September 30, 2018.

#### **Other Income, net**

Other income, net is largely comprised of interest income/(expense), dividends and franchise taxes.

#### **Application of Critical Accounting Policies**

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in our 2018 Annual Report on Form 10-K. We believe the following accounting procedures to be most critical to the judgments and estimates used in the preparation of our financial statements.

### *Accrued Research and Development Expenses*

As part of the process of preparing our financial statements, we are required to estimate our accrued expenses, particularly for product development costs. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments as necessary. Examples of estimated accrued research and development expenses include:

- fees paid to contractors in connection with the development of manufacturing processes for products in development;
- fees paid to CROs in connection with preclinical and clinical development activities;
- fees paid to contractors in connection with preparation of regulatory submissions; and
- fees paid to vendors related to product manufacturing, development and distribution of clinical study supplies.

We base our expenses related to pre-clinical and human studies on our estimates of the services received and efforts expended pursuant to contracts with multiple development contractors that conduct and manage development work and studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts may depend on factors such as the successful enrollment of subjects and the completion of specific study milestones. In accruing service fees, we will estimate the time period over which services will be performed, the completion of certain tasks, enrollment of subjects, study center activation and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual or prepayment accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. Based on limited historical experience, actual results have not been materially different from our estimates.

### *Identifiable Intangible Assets*

Identifiable intangible assets, composed of in-process research and development (“IPR&D”), are measured at fair values and are not amortized until commercialization of the underlying product candidate. Once commercialization occurs, these intangible assets will be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based upon reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require us to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, material delays in our development program or sustained decline in our market capitalization.

Indefinite-lived intangible assets are not subject to periodic amortization. Rather, indefinite-lived intangibles are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate impairment may have occurred.

## Research and Development Expenses

Research and development expenses are charged to operations as they are incurred.

## Leases

On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 and its related amendments, which changed our accounting for leases. As a result of this change, we recognized right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classified them as either operating or finance leases. The right-of-use assets and lease liabilities have been measured by the present value of remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable. See Note 1 and Note 6 of Notes to Unaudited Condensed Consolidated Financial Statements contained elsewhere in this report for additional details related to our adoption of the new lease accounting standard.

## Stock-Based Compensation

### Option Grants

We account for all share-based compensation payments issued to employees, directors, and non-employees using an option pricing model for estimating fair value. Accordingly, share-based compensation expense is measured based on the estimated fair value of the awards on the date of grant. We recognize compensation expense for the portion of the award that is ultimately expected to vest on a straight-line basis over the period during which the recipient renders the required services. The Company accounts for forfeitures of all share-based awards as they occur.

### Significant Factors, Assumptions and Methodologies Used in Determining Fair Value

We apply the fair value recognition provisions of ASC Topic 718, *Compensation-Stock Compensation*. We recognize share-based compensation expense ratably over the requisite service period, which in most cases is the vesting period of the award. Calculating the fair value of share-based awards requires that we make subjective assumptions.

We use the Black-Scholes option pricing model to value our stock option awards. Use of this valuation methodology requires that we make assumptions as to the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. As a publicly held company, we utilized our historical data to estimate expected stock price volatility.

We use the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No. 107, *Share-Based Payment*, to calculate the expected term of stock option grants to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees.

We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of options granted subject to a vendor consulting agreement, whereby the option vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Prior to January 1, 2019, stock options issued to consultants were revalued quarterly until fully vested, with any change in fair value expensed. Upon adoption of ASU No. 2018-07 on January 1, 2019, stock options issued to consultants are recorded at fair value on the date of grant and the award is recognized as an expense on a straight-line basis over the requisite service period. For awards subject to performance conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period when it is probable that the performance condition will be achieved. The following range of assumptions were used to value options granted for the three and nine months ended September 30, 2019 and 2018 and to re-measure stock options issued to consultants:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2019	2018	2019	2018
Volatility	108.03-108.06%	105.85-109.95%	108.03-111.34%	105.85-109.95%
Risk-free interest rate	1.59-1.89%	2.84-3.00%	1.59-2.65%	2.29-3.00%
Dividend yield	0.0%	0.0%	0.0%	0.0%
Expected life	6.0 years	6.0 years	6.0 years	6.0 years

The expected stock price volatility assumption was determined by examining the Company's historical volatility. We will continue to analyze our expected term assumptions as more historical data for our common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of our stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

Stock-based compensation expense associated with stock options and restricted stock granted to employees and non-employees was approximately \$2.3 million and \$2.8 million for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, we had approximately \$3.9 million of total unrecognized share-based compensation expense, which we expect to recognize over a weighted-average remaining vesting period of approximately 2.8 years. In future periods, our share-based compensation expense is expected to increase as a result of recognizing our existing unrecognized share-based compensation for awards that will vest and as we issue additional share-based awards to attract and retain our employees.

#### ***Basic and Diluted Net Loss per Share of Common Stock***

We compute basic net loss per share of common stock by dividing net loss applicable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects stock options. We compute diluted net loss per share of common stock by dividing the net loss applicable to common stockholders by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of stock options, warrants and convertible preferred stock outstanding during the period calculated in accordance with the treasury stock method, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between our basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2019 and 2018.

#### ***Emerging Growth Company Status***

Under Section 107(b) of the Jumpstart Our Business Startups Act of 2012, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

#### ***Current Operating Trends***

Our current research and development efforts are focused on developing MAT9001. Our research and development expenses consist of manufacturing work and the cost of drug ingredients used in such work, fees paid to consultants for work related to clinical trial design and regulatory activities, fees paid to providers for conducting various clinical studies as well as for the analysis of the results of such studies, and for other medical research addressing the potential efficacy and safety of our drugs. We believe that significant investment in product development is a competitive necessity, and we plan to continue these investments in order to be in a position to realize the potential of our product candidates and proprietary technologies.

We expect all our research and development expenses in the near-term will be incurred in support of our current and future preclinical and clinical development programs rather than technology development. These expenditures are subject to numerous uncertainties relating to timing and cost to completion. We test compounds in numerous preclinical studies for safety, toxicology and efficacy. At the appropriate time, subject to the approval of regulatory authorities, we expect to conduct early-stage clinical trials for each drug candidate. We anticipate funding these trials ourselves, and possibly with the assistance of federal grants, contracts or other agreements. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years, and the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

The commencement and completion of clinical trials for our products may be delayed by many factors, including lack of efficacy during clinical trials, unforeseen safety issues, slower than expected participant recruitment, lack of funding or government delays. In addition, we may encounter regulatory delays or rejections as a result of many factors, including results that do not support the intended safety or efficacy of our product candidates, perceived defects in the design of clinical trials and changes in regulatory policy during the period of product development. As a result of these risks and uncertainties, we are unable to accurately estimate the specific timing and costs of our clinical development programs or the timing of material cash inflows, if any, from our product candidates. Our business, financial condition and results of operations may be materially adversely affected by any delays in, or termination of, our clinical trials or a determination by the FDA that the results of our trials are inadequate to justify regulatory approval, insofar as cash in-flows from the relevant drug or program would be delayed or would not occur.

## Results of Operations

The following tables summarizes our revenues and operating expenses for the comparative periods presented (dollars in thousands):

	<b>Three Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
<b>Revenues</b>	\$ -	\$ -
<b>Expenses:</b>		
Research and development	\$ 2,671	\$ 1,380
General and administrative	1,890	1,574
Operating Expenses	<u>\$ 4,561</u>	<u>\$ 2,954</u>
<b>Sale of net operating losses (NOLs)</b>	\$ -	\$ -
	<b>Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
<b>Revenues</b>	\$ 90	\$ 120
<b>Expenses:</b>		
Research and development	\$ 7,815	\$ 5,095
General and administrative	5,460	5,505
Operating Expenses	<u>\$ 13,275</u>	<u>\$ 10,600</u>
<b>Sale of net operating losses (NOLs)</b>	\$ 1,007	\$ -

**Revenues.** Revenue was \$0 and \$0.1 million for the three and nine months ended September 30, 2019, respectively, compared to \$0 and \$0.1 million for the three and nine months ended September 30, 2018, respectively. Amounts earned consist of contract research revenue resulting from a grant with the Cystic Fibroses Foundation.

**Research and Development expenses.** Research and Development (R&D) expense for the three and nine months ended September 30, 2019 increased approximately \$1.3 million and \$2.7 million compared to the prior year periods. For the three-month period, R&D expenses increased primarily due to higher costs associated with manufacturing process development, clinical development and staffing & overhead. For the nine-month period, R&D expenses increased primarily due to higher costs associated with preclinical trials, clinical development and staffing & overhead.

**General and Administrative expenses.** General and administrative expense for the three and nine months ended September 30, 2019 increased approximately \$0.3 million and \$0 million compared to the prior year periods. For the three-month period, the increase in general and administrative expense was primarily due to higher compensation expense.

**Sale of net operating losses (NOLs).** The Company recognized approximately \$1.0 million and \$0 for the nine months ended September 30, 2019 and 2018, respectively, in connection with the sale of state net operating losses and state research and development credits to a third party under the New Jersey Technology Business Tax Certificate Program. The Company did not recognize any income from the sale of NOLs during the three months ended September 30, 2019 and 2018.

#### Liquidity and capital resources

##### Sources of Liquidity

We have funded our operations since inception through private placements of our preferred stock and our common stock and common stock warrants. As of September 30, 2019, we have raised a total of approximately \$100.1 million in gross proceeds and \$90.9 million, net, from sales of our equity securities.

As of September 30, 2019, we had cash and cash equivalents totaling \$32.7 million.

##### 2019 Common Stock Offering

On March 19, 2019, the Company closed an underwritten public offering of its common stock. The offering resulted in the sale of 27,272,727 shares to the public at a price of \$1.10 per share. The Company generated net proceeds of approximately \$27.8 million. The Company granted the underwriters a 30-day option (the "option") to purchase up to an additional 4,090,909 shares of common stock subject to the same terms and conditions. On March 28, 2019, an additional 2,199,259 shares were sold pursuant to the option at a price of \$1.10 per share, resulting in net proceeds to the Company of approximately \$2.3 million.

##### 2018 Series B Preferred Stock Offering

On June 19, 2018, the Company entered into a placement agency agreement with ThinkEquity, a Division of Fordham Financial Management, Inc., as placement agent, relating to the offering, issuance and sale of up to 8,000 shares of the Company's Series B Convertible Preferred Stock, par value \$0.0001 per share with a stated value of \$1,000 per share which are convertible into an aggregate of up to 16,000,000 shares of the Company's common stock at an initial conversion price of \$0.50 per share of common stock and an additional up to 7,200,000 shares of common stock issuable upon payment of dividends under the Series B Preferred Stock. The offering closed on June 21, 2018 raising a gross amount of approximately \$8 million with a net raise of approximately \$7.1 million after deducting issuance costs.

##### Cash Flows

The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each of the period set forth below (dollars in thousands):

	<b>Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
Cash used in operating activities	\$ (9,193)	\$ (7,702)
Cash used in investing activities	(406)	(536)
Cash provided by financing activities	29,842	7,508
Net increase/(decrease) in cash and cash equivalents and restricted cash	\$ 20,243	\$ (730)

### ***Operating Activities***

We have incurred significant costs in the area of research and development, including clinical, manufacturing, analytical, regulatory and other development costs. In addition, general and administrative expenses are incurred to operate as a public company, for personnel costs in the finance and executive functions, as well as costs associated with legal, accounting and investor relation services. Net cash used in operating activities was approximately \$9.2 million and \$7.7 million for the nine-month periods ended September 30, 2019 and 2018, respectively. We expect that there will be an increase in cash used in operations during the remainder of 2019 due to higher research and development expenses as we continue to move our product candidates and delivery platform forward in their development cycles.

### ***Investing Activities***

Approximately \$0.4 million and \$0.5 million of cash was used in investing activities for the nine-month periods ended September 30, 2019 and 2018, respectively. The investments were primarily related to our laboratory facility.

### ***Financing Activities***

Net cash provided by financing activities was approximately \$29.8 million for the nine months ended September 30, 2019. The cash provided by financing activities was primarily due to the March public offering of common stock. This compares to approximately \$7.5 million provided by financing activities in the prior year period, primarily from the sale of Series B Preferred Stock and other equity offerings.

### ***Funding Requirements and Other Liquidity Matters***

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

- conduct further preclinical and clinical studies of MAT9001, our lead product candidate;
- support the conduct of further clinical studies of MAT2203, even if such studies are partially financed with non-dilutive funding from the NIH;
- seek to discover and develop additional product candidates;
- seek regulatory approvals for any product candidates that successfully complete clinical trials;
- require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
- maintain, expand and protect our intellectual property portfolio;
- hire additional clinical, quality control and scientific personnel; and
- add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts and personnel and infrastructure necessary to help us comply with our obligations as a public company.

We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditures requirements through 2020.



Until such time, if ever, that we can generate product revenues sufficient to achieve profitability, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, government or other third party funding, collaborations and licensing arrangements. We do not have any committed external source of funds other than limited grant funding from the NIH. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interest of our stockholders may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights of our common stockholders. Debt financing and preferred equity financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. Securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management's ability to oversee the development of our product candidates.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

#### ***Contractual Obligations and Commitments***

There have been material changes from the disclosures relating to our contractual obligations reported in our Annual Report on Form 10-K for the year ended December 31, 2018 as a result of our adoption of Accounting Standards Update No. 2016-02 and its related amendments, which changed our accounting for leases. See Note 1 and Note 6 of Notes to Unaudited Condensed Consolidated Financial Statements contained elsewhere in this report for additional details related to our adoption of the new lease accounting standard.

#### ***Off-Balance Sheet Arrangements***

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.

### **Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operation. We do not have any foreign currency or other derivative financial instruments.

### **Item 4. CONTROLS AND PROCEDURES**

#### ***Evaluation of Disclosure Controls and Procedures.***

#### ***Disclosure Controls and Procedures:***

As of September 30, 2019, under the supervision and with the participation of our principal executive officer and principal financial officer we have evaluated, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based on that evaluation, our principal executive officer and principal financial officer concluded that because remediation of the material weaknesses in our internal control over financial reporting described in our 2018 Form 10-K has not been completed as described below, our disclosure controls and procedures were not effective at September 30, 2019.

***Management's Report on Internal Control over Financial Reporting:***

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, any projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

As previously disclosed in our 2018 Form 10-K, an evaluation was conducted under the supervision and with the participation of management, including our CEO and CFO, on the effectiveness of the Company's internal control over financial reporting as of December 31, 2018 based on criteria related to internal control over financial reporting described in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013 Framework). Based on this evaluation, management determined that because of the material weaknesses described below, the Company's internal control over financial reporting was not effective as of December 31, 2018.

We did not maintain an effective control environment over the internal control activities to ensure the processing of and reporting of transactions are complete, accurate and timely. Specifically, we have not designed and implemented a sufficient level of formal financial reporting and operating policies and procedures that define how transactions should be initiated, processed, recorded and reported, including presentation and disclosure in the consolidated financial statements.

Furthermore, we did not maintain a sufficient complement of accounting personnel with sufficient knowledge and training in the application of U.S. GAAP. This deficiency led to the failure to maintain, document and apply appropriate account standards in the areas of income tax provisions, convertible equity securities, and stock-based compensation.

The material weaknesses identified above could result in a misstatement to the aforementioned account balances and disclosures that would result in a material misstatement to the annual or interim consolidated financial statements would not be prevented or detected on a timely basis. The Company believes the material weakness continues to exist because the Company's remediation effort is ongoing.

***Changes in Internal Control Over Financial Reporting:***

Other than the continued implementation of the remediation plan described below, there have been no changes in our internal control over financial reporting during the three months ended September 30, 2019, that have materially affected, or are reasonably likely not to materially affect, our internal control over financial reporting.

**Remediation Plan:**

During 2019, Management has initiated a remediation plan to address the control deficiencies that led to the material weaknesses. The remediation plan includes, but is not limited to:

- The enhancement of our financial reporting and operating policies and procedures, including design and implementation of additional controls over the initiation, processing and recording of transactions to ensure such transactions are complete, accurate and recorded in a timely manner.
- Hiring and training existing personnel on the application of accounting principles and adherence to newly adopted policies, procedures and controls.
- The Company has retained the services of outside consultants, with relevant accounting experience, skills and knowledge in U.S. GAAP, working under the supervision and direction of the Company's management, to supplement the Company's accounting personnel.

**PART - II OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

None.

**Item 1A. RISK FACTORS**

There were no material changes from the risk factors set forth under Part I, Item 1A., "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. You should carefully consider these factors in addition to the other information set forth in this report which could materially affect our business, financial condition or future results. The risks and uncertainties described in this report and in our Annual Report on Form 10-K for the year ended December 31, 2018, as well as other reports and statements that we file with the SEC, are not the only risks and uncertainties facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also have a material adverse effect on our financial position, results of operations or cash flows.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**Item 3. DEFAULTS UNDER SENIOR SECURITIES**

None.

**Item 4. MINE SAFETY DISCLOSURES**

Not applicable.

**Item 5. OTHER INFORMATION**

Not applicable.

**Item 6. EXHIBITS**

See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MATINAS BIOPHARMA HOLDINGS, INC.**

BY:

*/s/ Jerome D. Jabbour*

\_\_\_\_\_  
Jerome D. Jabbour  
Chief Executive Officer (Principal Executive Officer)

Dated: November 13, 2019

*/s/ Keith A. Kucinski*

\_\_\_\_\_  
Keith A. Kucinski  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

Dated: November 13, 2019

EXHIBIT INDEX

- \*31.1 [Certification of Chief Executive Officer](#)
- \*31.2 [Certification of Chief Financial Officer](#)
- \*\*32.1 [Section 1350 Certifications](#)
- \*101.1 XBRL Instance Document.
- \*101.2 XBRL Taxonomy Extension Schema Document.
- \*101.3 XBRL Taxonomy Extension Calculation Linkbase Document.
- \*101.4 XBRL Taxonomy Extension Definition Linkbase Document.
- \*101.5 XBRL Taxonomy Extension Label Linkbase Document.
- \*101.6 XBRL Taxonomy Extension Presentation Linkbase Document.
  - \* Filed herewith.



CERTIFICATION

I, Jerome D. Jabbour, certify that:

1. I have reviewed this report on Form 10-Q of Matinas BioPharma Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2019

By /s/ Jerome D. Jabbour  
Name: Jerome D. Jabbour  
Title: Chief Executive Officer

---





CERTIFICATION

I, Keith A. Kucinski, certify that:

1. I have reviewed this report on Form 10-Q of Matinas BioPharma Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2019

By: /s/ Keith A. Kucinski  
Name: Keith A. Kucinski  
Title: Chief Financial Officer

---



SECTION 1350 CERTIFICATIONS

Pursuant to 18 U.S.C. §1350 as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Matinas BioPharma Holdings, Inc. (the "Company") hereby certify that to their knowledge and in their respective capacities that the Company's quarterly report on Form 10-Q to which this certification is attached (the "Report"), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2019

By: /s/ Jerome D. Jabbour

Name: Jerome D. Jabbour

Title: Chief Executive Officer

Date: November 13, 2019

By: /s/ Keith A. Kucinski

Name: Keith A. Kucinski

Title: Chief Financial Officer

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Matinas BioPharma Holdings, Inc. and will be retained by Matinas BioPharma Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

---

